On March 15, 2023 Jazz Pharmaceuticals plc (Nasdaq: JAZZ) reported that the company, along with its partners, will present five new abstracts at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting from April 14-19, 2023 (Press release, Jazz Pharmaceuticals, MAR 15, 2023, View Source [SID1234628848]). Research findings to be presented include data from company-sponsored and collaborative trials studying Zepzelca (lurbinectedin), zanidatamab and JZP898.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The data Jazz and our partners are presenting at AACR (Free AACR Whitepaper) this year demonstrate our commitment to advancing the next generation of oncology care, including our ongoing research for lurbinectedin," said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. "Over the last year, Jazz has added promising new immuno-oncology and targeted therapy candidates to our pipeline – including zanidatamab, a novel late-stage HER2-targeted bispecific antibody – and progressed ongoing development programs with the goal of improving standards of care across multiple cancer types with significant unmet need and poor outcomes."

Data highlights at the AACR (Free AACR Whitepaper) Annual Meeting include:

A poster presentation evaluating the role of SLFN11 expression in predicting response to lurbinectedin, a DNA damaging agent, in human small cell lung cancer (SCLC) cell lines and in vivo models. Results demonstrate that efficacy may be correlated to SLFN11 protein expression, consistent with the RNA level association.1
A poster presentation featuring data identifying MCL1 as a specific lurbinectedin target and demonstrating anti-tumor activity of lurbinectedin in combination with a specific BCL2 inhibitor and with a specific BCL2L1 inhibitor in in vivo and in vitro models.2
A poster presentation titled "ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers."
The AACR (Free AACR Whitepaper) abstracts are available at: View Source!/10828/

The full list of Jazz-supported presentations at the 2023 AACR (Free AACR Whitepaper) Annual Meeting are:

Zepzelca (lurbinectedin) Presentations

Presentation Title

Author

Presentation Details

High SLFN11 expression correlates with sensitivity to lurbinectedin in small cell lung cancer (SCLC) models

Gupta A., et al.

Type: Poster

Session: Biomarkers of Therapeutic Benefit 2

Date: Monday, April 17, 2023, 9:00 AM – 12:30 PM

Abstract number: 2145

Lurbinectedin exhibits combinatorial activity with BCL2/BCL2L1 inhibitors in vitro and in vivo by modulation of MCL1 expression

Vaidya K.S., et al.

Type: Poster

Session: Cell Death Pathways/ Molecular Classifications of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes

Date: Wednesday, April 19, 2023, 9:00 AM – 12:30 PM

Abstract number: 6155

Lurbinectedin shows potent activity in all four molecular subtypes of small cell lung cancer (SCLC) and POU2F3 and SLFN11 are biomarkers for a better response

Diez M.M., et al.

Type: Poster

Session: DNA-reactive Agents, HDAC and Methyltransferase Inhibitors, and Tubulin Agents

Date: Wednesday, April 19, 2023, 9:00 AM – 12:30 PM

Abstract number: 6247

Zanidatamab Presentation*

Presentation Title

Author

Presentation Details

ERBB2 amplification detected in ctDNA as a surrogate for tumor tissue FISH analysis of HER2 status in phase 1 study with zanidatamab for the treatment of locally advanced or metastatic HER2 expressing cancers

Shpektor D., et al.

Type: Poster

Session: Phase I Clinical Trials 2

Date: Tuesday, April 18, 2023, 1:30 PM – 5:00 PM

Abstract number: CT278

*Clinical trial abstract texts are embargoed until noon ET on April 14, 2023.

JZP898 Presentation

Presentation Title

Author

Presentation Details

WTX-613, (JZP898) a selectively activated IFNα INDUKINE molecule, reprograms the tumor microenvironment and generates robust anti-tumor immunity as a monotherapy and in combination with checkpoint inhibitors

Nirschl CJ, et al.

Type: Poster

Session: Immunomodulatory Agents and Interventions 1

Date: Monday April 17, 2023 9:00 AM – 12:30 PM

Abstract number: 1817

On March 15, 2023 Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present new research enabling accurate detection and study of the functional relevance of the novel target PVRIG following correction of the GENCODE gene model, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting on April 14-19, 2023, in Orlando, Florida (Press release, Compugen, MAR 15, 2023, View Source [SID1234628847]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"One of the biggest challenges in bringing new treatments to cancer patients, is understanding the complex disease biology," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. "Single cell technology has revolutionized the study of cell populations, particularly immune cells and has been a key technology used by many scientists involved in cancer immunotherapy research. The research we are presenting at AACR (Free AACR Whitepaper) identified an inaccuracy in the single cell gene model technology. By correcting the GENCODE gene model, the most widely used gene model in single cell analysis platforms, we believe that we are enabling a more accurate detection of PVRIG, thereby facilitating the advancement of worldwide research of this pathway. We believe that this advancement could lead to the development of new cancer immunotherapies. As a leader in the DNAM-1 axis space, targeting both PVRIG and TIGIT pathways, we are focused on proof-of-concept studies in cancer patients treated with the triple combination of our potential first-in-class anti-PVRIG, COM701 our potential best-in-class anti-TIGIT, COM902, and a PD-1 inhibitor, with the goal of maximizing clinical benefit for patients."

Poster details:

Session Date and Time: Tuesday April 18, 2023, 9:00 AM – 12:30 PM ET
Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science
Session Title: Algorithms and Statistical Methods
Poster Title: Gene model correction for PVRIG and TIGIT in single cell sequencing data enables accurate detection and study of its functional relevance
Published Abstract Number: 4292

The abstract is available on Compugen’s website at www.cgen.com

On March 15, 2023 Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class therapies targeting the Hippo pathway, reported that the first clinical data for a cancer treatment targeting the Hippo pathway will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 (Press release, Vivace Therapeutics, MAR 15, 2023, View Source [SID1234628846]). Results from the company’s Phase 1 clinical study of its first-in-class transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, will be presented by Timothy A. Yap, Ph.D., of the University of Texas, M.D. Anderson Cancer Center, during an oral plenary session at the conference. The AACR (Free AACR Whitepaper) conference is being held April 14-19, 2023, in Orange, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1 study (View Source) is a multi-center, open label trial designed to evaluate the safety, tolerability, pharmacokinetics (PK) and biological activity of VT3989 in patients with refractory metastatic solid tumors, including refractory pleural malignant mesothelioma. The study included both a dose escalation and a dose expansion phase, the latter of which also enrolled patients with neurofibromatosis 2 (NF2) mutant tumors.

Details of the oral presentation at the AACR (Free AACR Whitepaper) conference are as follows:

Presentation #CT006:

Title: First-in-Class, First-in-Human Phase 1 Trial of VT3989, an inhibitor of Yes-Associated Protein (YAP)/Transcriptional Enhancer Activator Domain (TEAD), in Patients (pts) with Advanced Solid Tumors Enriched for Malignant Mesothelioma and Other Tumors with Neurofibromatosis 2 (NF2) Mutations

Presenting Author: Timothy A. Yap, Ph.D., University of Texas, M.D. Anderson Cancer Center

Session: CTPL02: Hope for Rare Cancers: Novel Targeted and Immunotherapy Agents

Date/Time: Sunday, April 16, 2023, 3:30 – 3:45 p.m. Eastern

Location: W Hall A2-3
Vivace’s proprietary compounds, including lead development candidate VT3989, inhibit palmitoylation of members of the TEAD protein family, including both covalent and non-covalent inhibitors. Pre-clinical research and development activities have demonstrated that VT3989 is active as a monotherapy against tumors that rely upon dysfunction of the Hippo pathway, and in combination with other anti-cancer therapies in additional tumor types.

On March 15, 2023 Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported that it will host a conference call and live webcast on Tuesday, March 28, 2023 at 8:30 am EDT (5:30 am PDT) to report fourth quarter and full-year 2022 financial results and provide recent corporate updates (Press release, Aadi Bioscience, MAR 15, 2023, View Source [SID1234628845]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in advance here: Conference Registration (vevent.com). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the website for at least 30 days.

On March 15, 2023 Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with solid tumors, reported that the Company will be presenting preclinical and clinical data on its lead asset TAC01-HER2 for the treatment of human epidermal growth factor receptor 2 (HER2) positive solid tumors at the 2023 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place in Orlando, April 14-19 (Press release, Triumvira Immunologics, MAR 15, 2023, View Source [SID1234628844]). The presentations will include updated clinical data and product characterization from the ongoing Phase I/II trial of autologous TAC01-HER2 (NCT04727151) in patients with solid tumors and preclinical data on an allogeneic HER2-TAC T cell product.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to present additional validation of our lead clinical program TAC01-HER2, currently in Phase I/II trials, supporting the efficiency of our proprietary Cocoon platform to manufacture potent autologous TAC01-HER2 cells using leukocytes from cancer patients," said Deyaa Adib, M.D., Chief Medical Officer of Triumvira Immunologics. "Interim results will also be presented from our ongoing Phase I/II trial investigating the safety and efficacy of autologous TAC01-HER2 in HER2+ refractory solid tumors demonstrating a favorable safety profile and promising clinical activity as evident by reduction of measurable disease and prevention of fast cancer progression in the majority of patients enrolled in the Phase I trial. Further, we will present new preclinical data from our allogeneic T cell-based products in development demonstrating their potential to avoid graft versus host disease."

Presentation Details:

Title: A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC01-HER2 in Relapsed or Refractory Solid Tumors
Authors: Ecaterina E. Dumbrava, MD, Daniel Olson, MD, Samuel Saibil, MD, Brooke Pieke, Mridula A. George, MD, Riemke Bouvier, Kelly Gruber, Kara Moss, Nathan Ternus, Maria Apostolopoulou, Deyaa Adib, MD, and Benjamin L. Schlechter, MD.
Session: Phase II Clinical Trial 2
Date and Time: Tuesday, April 18, 2023, from 9 a.m. to 12:30 p.m. EDT
Abstract Number: CT234

Title: Patient-derived TAC01-HER2 TAC T cells produced in Cocoon Platform are highly functional in models of solid tumors
Authors: Ling Wang, Stacey X. Xu, Tania Benatar, Ritu R. Randhawa, Philbert Ip, Prabha Lal, Thanyashanthi Nitya-Nootan, Laura Shaver, Heather MacGregor, Suzy Prosser, Sadhak Sengupta, Christopher W. Helsen, and Andreas G. Bader
Session: Adoptive Cell Therapy 2
Date and Time: Monday, April 17, 2023, from 1:30 p.m. to 5 p.m. EDT
Abstract Number: 3188

Title: Preclinical characterization of allogeneic Vγ9Vδ2 HER2-TAC T cells for the treatment of HER2-positive solid tumors
Authors: Suzanna L. Prosser, Stacey X. Xu, Ling Wang, Ritu R. Randhawa, Sailaja Pirati, Laura Ravensbergen, Seungmi Yoo, Miyoung Jung, Laurentia Gheorghiu, Angel Gomez, Gurleen Sandhu, Chris Ayers, Donna Rill, Christopher W. Helsen, Andreas G. Bader.
Session: CAR T-cell Therapy 1
Date and Time: Monday, April 17, 2023, from 9 a.m. to 12:30 p.m. EDT
Abstract Number: 1773

Abstracts are currently available on the AACR (Free AACR Whitepaper) website. A copy of the presentations will also be available after the closure of the meeting on April 19, under the Presentations & Publications tab of the News & Resources section of the Company’s website.